Physician profile
Basil M Dudar
NPI 1407804958
$2,807.24
in general payments reported to CMS, 2019-2025
17 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,777 · 2020: $122 · 2021: $220 · 2022: $345 · 2023: $59.91 · 2024: $118 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.55 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,758.72 | 2019 | |
| Amgen INC. | $275.49 | 2021-2025 | Repatha |
| Medtronic, INC. | $192.53 | 2022-2025 | Closurefast |
| Boston Scientific Corporation | $134.55 | 2020-2024 | Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.81 | 2024-2025 | Lifevest |
| Cordis US Corp. | $51.63 | 2023-2024 | Mynx Control, Mynxgrip |
| E.R. Squibb & Sons, L.L.C. | $45.39 | 2022-2025 | Camzyos |
| Kiniksa Pharmaceuticals, Ltd. | $45.05 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $44.08 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $42.01 | 2021 | |
| Cardiva Medical, INC. | $25.05 | 2025 | Cardiva Vascade 6/7f Vcs |
| Novo Nordisk INC | $24.82 | 2024 | Wegovy |
| Teleflex LLC | $21.80 | 2025 | Guideliner |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Heartflow, INC. | $17.95 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $17.90 | 2019 | |
| Shockwave Medical, INC | $16.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Dudar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.